Aligos Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aligos Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.4 times its market value (net cash). Higher than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-413.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 95% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 84%
Sales fell 84% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-84% / -40%In 3 years sales changed by -84% while total assets changed by -40%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-22.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 56% of Healthcare companies in United States.
Cash Cushion Ratio
2.4× cashCash, after subtracting all debt, is 2.4 times its market value (net cash).
Higher than 96% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Aligos Therapeutics, Inc. made a loss over the last year. Aligos Therapeutics, Inc. owes $0.52 for every $1 it owns. Aligos Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAligos Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.94The share price is 0.94 times Aligos Therapeutics, Inc.'s book value per share, lower than 79% of Healthcare companies in United States.
Market cap
$30 MThe total market value of all of Aligos Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 79% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$32 MWhat Aligos Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.11Net worth divided by the number of shares. The share price of $4.82 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-113.6%Aligos Therapeutics, Inc. lost 113.6% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
Owes vs Owns
0.52×Aligos Therapeutics, Inc. owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Dividend yield
NoneAligos Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-45%Revenue fell 45% in the year to Dec 2025, and shrank 46% a year on average over 3 years.
Profit growth
LossAligos Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-1106.7%Aligos Therapeutics, Inc. lost $1107 for every $100 of revenue.
Cash vs debt
Net cashAligos Therapeutics, Inc. held $73 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aligos Therapeutics, Inc.: $30 M ÷ $32 M (30 Jun 2026) = 0.9.
What is Aligos Therapeutics, Inc.'s return on equity?
Aligos Therapeutics, Inc. lost 113.6% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
How much does Aligos Therapeutics, Inc. owe compared with what it owns?
Aligos Therapeutics, Inc. owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Does Aligos Therapeutics, Inc. pay a dividend?
No. Aligos Therapeutics, Inc. does not currently pay a dividend.
Is Aligos Therapeutics, Inc.'s revenue growing?
Revenue fell 45% in the year to Dec 2025, and shrank 46% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.